The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma.
Premal D Lulla,Ifigeneia Tzannou,Spyridoula Vasileiou,George Carrum,Carlos A Ramos,Rammurti Kamble,Tao Wang,Mengfen Wu,Mrinalini Bilgi,Adrian P Gee,Shivani Mukhi,Betty Chung,Linghua Wang,Ayumi Watanabe,Manik Kuvalekar,Mira Jeong,Yumei Li,Shamika Ketkar,Matthew French-Kim,Bambi Grilley,Malcolm K Brenner,Helen E Heslop,Juan F Vera,Ann M Leen
DOI: https://doi.org/10.1126/scitranslmed.aaz3339
IF: 17.1
2020-01-01
Science Translational Medicine
Abstract:Multiple myeloma (MM) is an almost always incurable malignancy of plasma cells. Despite the advent of new therapies, most patients eventually relapse or become treatment-refractory. Consequently, therapies with nonoverlapping mechanisms of action that are nontoxic and provide long-term benefit to patients with MM are greatly needed. To this end, we clinically tested an autologous multitumor-associated antigen (mTAA)-specific T cell product for the treatment of patients with high-risk, relapsed or refractory MM. In this study, we expanded polyclonal T cells from 23 patients with MM. T cells whose native T cell receptors were reactive toward five myeloma-expressed target TAAs (PRAME, SSX2, MAGEA4, Survivin, and NY-ESO-1) were enriched ex vivo. To date, we have administered escalating doses of these nonengineered mTAA-specific T cells (0.5 x 10(7) to 2 x 10(7) cells/m(2)) to 21 patients with MM, 9 of whom were at high risk of relapse after a median of 3 lines of prior therapy and 12 with active, relapsed or refractory disease after a median of 3.5 prior lines. The cells were well tolerated, with only two transient, grade III infusion-related adverse events. Furthermore, patients with active relapsed or refractory myeloma enjoyed a longer than expected progression-free survival and responders included three patients who achieved objective responses concomitant with detection of functional TAA-reactive T cell clonotypes derived from the infused mTAA product.